ISPOR 19TH ANNUAL EUROPEAN CONGRESS EXAMINES INCLUSION OF FUTURE MEDICAL COSTS IN HEALTH TECHNOLOGY ASSESSMENT GUIDELINES

Published Nov 2, 2016
Vienna, Austria—2 November 2016—The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) held an issue panel entitled, Should Health Technology Assessment Guidelines Recommend Inclusion of Future Medical Costs?, at the Society’s 19th Annual European Congress in Vienna, Austria.  The issue panel was moderated by Andrew Briggs, DPhil, MSc, William R, Lindsay Chair of Health Economics and Professor of Health Economics, University of Glasgow, Glasgow, UK. Panelists for the issue panel included:
  • Alec Morton, PhD, Professor, Management Science, University of Strathclyde, Glasgow, UK
  • Pieter van Baal, PhD, Associate Professor, Institute for Health Policy and Management, Erasmus University Rotterdam, Rotterdam, The Netherlands
  • Ad Antonisse, MSc, Director Economic Affairs (Market Access and Public Affairs), AstraZeneca, Zoetermeer, The Netherlands
This session explored whether health technology assessment (HTA) guidelines should recommend the inclusion of “unrelated future costs” of a medical technology. Recently, Dutch HTA guidelines were changed to recommend inclusion of future, unrelated medical costs. Currently, however, many HTA guidelines exclude future medical costs from an appraisal. For example, the costs of caring for a patient with dementia after preventing death from stroke would not be included in a cost effectiveness analysis of a thrombolysis treatment. The panelists presented the benefits and disadvantages of including future, unrelated costs in HTA guidelines. Alec Morton, PhD provided a summary of theoretical arguments for and against inclusion of future unrelated medical costs. Pieter van Baal, PhD reviewed approaches for how these future costs can be estimated in practice. Ad Antonisse, MSc provided the industry perspective on the issue. Additional information on the ISPOR 19th Annual European Congress can be found here. Released presentations from the congress can be found here. Interested parties can follow news and developments from the conference on social media using the hashtag #ISPORVienna.

###

Related Stories

Health Equity Research Goes Global—Without Waiting for Perfect Data

Feb 9, 2026

Value in Health Regional Issues announced the publication of a special collection of research papers in showing that meaningful progress in health equity research is occurring across regions and in settings with different data environments and policy needs.

International Study Confirms Universally Applicable Framework for Defining Digital Health Interventions

Jan 21, 2026

Value in Health, the official journal of ISPOR—The Professional Society for Health Economics and Outcomes Research, announced today the publication of a comprehensive international study demonstrating that the PICOTS-ComTeC framework serves as an effective universal standard for defining patient-facing digital health interventions. The report, “Towards a Common Ground for Defining Digital Health Interventions, Mapping Digital Health Frameworks to PICOTS-ComTeC: An ISPOR Special Interest Group Report” was published in the January 2026 issue of Value in Health.

ISPOR Releases New 2026-2027 Top 10 HEOR Trends Report

Jan 20, 2026

ISPOR—The Professional Society for Health Economics and Outcomes Research (HEOR) announced today the publication of its new “2026-2027 Top 10 HEOR Trends Report.” The Society publishes this report every two years as part of its horizon scanning and monitoring of the trends that affect healthcare decision making around the world.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×